Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts

 April 3, 2026

BioSpace

After a flurry of deals over the past week from Eli Lilly, Merck and Biogen, analysts predict more M A action from other big names, including Novartis, Amgen and AbbVie.

M&A / DealsRead full story

Post navigation

Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences →
← Trump Hits Drugmakers With 100% Tariff but Carve-outs Soften the Blow

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com